Roche Aktie

42,80 EUR +0,80 EUR +1,89 %

08:02:57

FSE

41,33 USD -1,09 USD -2,58 %

28.10.2025

LSE

Roche jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

KGV23,66Div. Rendite2,45%

WKN891106

ISINUS7711951043

SymbolRHHBY

Roche Aktien News

Sortieren:Datum Meistgelesen

16.12.25PR NewswireRoche announces U.S. launch of next-generation cobas 6800/8800 systems and software, enhancing laboratory efficiency and testing capabilities

11.12.25Roche Holding AGRoche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu

10.12.25Roche Holding AGRoche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer

WerbungRoche-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

09.12.25Roche Holding AGRoche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark

09.12.25Roche Holding AGEuropean Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis

08.12.25Roche Holding AGRoche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas

08.12.25Roche Holding AGRoche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study

02.12.25Roche Holding AGRoche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis)

19.11.25Roche Holding AGEuropean Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma

18.11.25Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer

03.11.25Roche Holding AGPositive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus

30.10.25Roche Holding AGRoche purchases shares in tender offer for 89bio, Inc

29.10.25Roche Holding AGRoche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue

28.10.25Roche Holding AGPositive phase III results for Roche’s Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome

23.10.25Roche Holding AGChanges to the Roche Enlarged Corporate Executive Committee

23.10.25Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised

20.10.25Roche Holding AGFDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis

18.10.25Roche Holding AGRoche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer

17.10.25Roche Holding AGCHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis

16.10.25Roche Holding AGRoche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025

13.10.25PR NewswireRoche's Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology

13.10.25Roche Holding AGRoche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types

06.10.25Roche Holding AGRoche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches new comprehensive chronic kidney disease (CKD) algorithm panel

03.10.25Roche Holding AGChange in the Roche Board of Directors

01.10.25Roche Holding AGRoche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash

30.09.25Roche Holding AGData show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks

24.09.25Roche Holding AGRoche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025

22.09.25Roche Holding AGPositive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer

19.09.25Roche Holding AGCHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma

18.09.25PR NewswireRoche achieves first CLIA 'Moderate Complexity' categorization for Ionify® 25-Hydroxy Vitamin D total test

18.09.25Roche Holding AGRoche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH

16.09.25PR NewswireRoche receives CE Mark for Accu-Chek SmartGuide Continuous Glucose Monitoring and mySugr App integration, offering an enhanced diabetes management experience

05.09.25PR NewswireRoche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients

05.09.25Roche Holding AGNew data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)

04.09.25Roche Holding AGRoche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)

30.08.25Roche Holding AGRoche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

25.08.25Roche Holding AGRoche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA

01.08.25Roche Holding AGRoche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.